1-(3,5-Dicyclopropylpyridin-2-yl)piperazine → HCID 86676773, Verbindung
Reaktionsgleichung
[Br:1][C:2]1[CH:10]=[CH:9][C:5]([C:6]([OH:8])=O)=[C:4]([CH3:11])[N:3]=1.[CH:12]1([C:15]2[C:16]([N:24]3[CH2:29][CH2:28][NH:27][CH2:26][CH2:25]3)=[N:17][CH:18]=[C:19]([CH:21]3[CH2:23][CH2:22]3)[CH:20]=2)[CH2:14][CH2:13]1>>[Br:1][C:2]1[N:3]=[C:4]([CH3:11])[C:5]([C:6]([N:27]2[CH2:28][CH2:29][N:24]([C:16]3[C:15]([CH:12]4[CH2:13][CH2:14]4)=[CH:20][C:19]([CH:21]4[CH2:23][CH2:22]4)=[CH:18][N:17]=3)[CH2:25][CH2:26]2)=[O:8])=[CH:9][CH:10]=1Komponenten
3
Versuchsvorschrift
Using 6-bromo-2-methylnicotinic acid (604 mg) and 1-(3,5-dicyclopropylpyridin-2-yl)piperazine (816 mg) described in Preparation Example 88 and by the reaction and treatment in the same manner as in Preparation Example 111, the title compound (695 mg) was obtained.
Aufarbeitung
- customdescribed in Preparation Example 88 and by the reaction and treatment in the same manner as in Preparation Example 111